JO
MAZE

John Overdeck’s Maze Therapeutics MAZE Stock Holding History

John Overdeck’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.76M Buy
192,952
+177,107
+1,118% +$4.64M ﹤0.01% 2004
2026
Q1 		$473K Buy
15,845
+8,600
+119% +$380K ﹤0.01% 3773
2025
Q4 		$300K Sell
7,245
-3,905
-35% -$134K ﹤0.01% 3572
2025
Q3 		$289K Buy
+11,150
New +$188K ﹤0.01% 3232

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

John Overdeck's MAZE Position: Q2 2026 in Review

John Overdeck increased its Maze Therapeutics (MAZE) stake by 1,118% in Q2 2026, buying an estimated $4.64M and bringing the position to 192,952 shares worth $5.76M. The position accounts for ﹤0.01% of the portfolio, ranked #2004.

John Overdeck first reported a position in MAZE in Q3 2025 and has held it in 4 quarters since. 161 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • John Overdeck held 192,952 shares of Maze Therapeutics worth $5.76M as of Q2 2026.
  • John Overdeck bought 177,107 Maze Therapeutics shares in Q2 2026, an estimated $4.64M.
  • Maze Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2004 holding.
  • John Overdeck first reported a position in Maze Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 161 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.